← Leaderboards
Thomas A Dix
Argolyn Bioscience, Inc.
$1,774,146
Attributed
$1,774,146
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $641K · FY2005–07$1M$750K$500K$250K$0
'05
'06
'07
Funding mix
By agency
NIH$1,774,146 · 4
By mechanism
R44$1,345,456 · 1
R41$264,745 · 2
R43$163,945 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Drug Design /Synthesis /Production”
- Dennis L. Kasper · Harvard Medical School$26,605,444
- Myron Max Levine · University Of Maryland Baltimore$22,074,862
- George R Painter · Chimerix, Inc.$19,230,662
- Donald L Fine · Dynport Vaccine Company, Llc$9,996,228
- Dennis E. Hruby · Oregon State University$9,654,233
- William C Olson · Progenics Pharmaceuticals, Inc.$8,361,679
Research focus
Drug Design /Synthesis /ProductionPeptide Chemical SynthesisReceptor BindingPainAntipsychotic AgentsLaboratory RatNeurotensinPeptidesSchizophreniaBiological AvailabilityBenchmarkingBaseAnimalsBiomimeticsAminoacidAtypical AntipsychoticCanis FamiliarisAttenuationAnalogCatalepsyChargeClassClinical ResearchBrain
Grant awards (6)
Novel Neurotensin Analogs as Antischizophrenics$392,525
R44 · FY2007 · MH · contact PI
Novel Neurotensin Analogs as Antischizophrenics$477,047
R44 · FY2006 · MH · contact PI
Development of Neurotensin-based Analgesics$163,945
R43 · FY2006 · GM · contact PI
Novel Neurotensin Analogs as Antischizophrenics$475,884
R44 · FY2005 · MH
Novel Neurotensin Analogs as Antischizoprenics$139,466
R41 · FY2002 · MH
NON-NATURAL AMINO ACIDS IN PEPTIDE DRUG DEVELOPMENT$125,279
R41 · FY2002 · DA